<DOC>
	<DOCNO>NCT02985268</DOCNO>
	<brief_summary>At present , optimal treatment strategy heart failure patient moderate-to-severe ( 3+ ) severe ( 4+ ) mitral regurgitation class IIa recommendation CRT uncertain.Whether patent also treat functional mitral regurgitation CRT also remain unclear . We therefore propose randomize 2x2 factorial design patient population understand impact CRT transcatheter mitral valve repair MitraClip functional status quality life .</brief_summary>
	<brief_title>Evaluation Outcomes CRT MitraClip Treatment Low Ejection Fraction Functional Mitral Regurgitation HF</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>1 . Symptomatic moderatetosevere ( 3+ ) severe ( 4+ ) functional mitral regurgitation due cardiomyopathy either ischemic nonischemic etiology determine transthoracic echocardiogram ( TTE ) , confirm Echocardiography Core Lab ( ECL ) ; 2 . Symptomatic heart failure define New York Heart Association ( NYHA ) class II , III ambulatory IV ; 3 . Treatment compliance optimal medical therapy heart failure least 30 day ; Optimal medical therapy define : Maximum tolerated betablocker , angiotensin convert enzyme inhibitor ( ACE ) angiotensin receptor blocker ( ARB ) , aldosterone antagonist ( per ACCF/AHA Guidelines judge HF specialist investigator site confirm Clinical Eligibility Committee ) . 4 . Left ventricular ejection fraction ≤ 35 % , assess one follow method : echocardiography , contrast leave ventriculography , gate blood pool scan cardiac magnetic resonance imaging ( MRI ) ; 5 . Class IIa indication cardiac resynchronization therapy : 1 . Left bundle branch block ( LBBB ) QRS duration 120149 m ; 2 . Right bundle branch block ( RBBB ) QRS ≥ 150 ms. 6 . Clinical agreement amongst local investigator patient offer surgical intervention ; 7 . The primary regurgitant jet , opinion MitraClip implanting investigator , successfully treat MitraClip . Treatment commissural mitral regurgitation may treat discretion operator . All major jet contribute secondary MR treat MitraClip ; 8 . Ability perform sixminute walk test ( 6MWT ) without substantial physical limitation without use walker wheelchair distance walk 6 minute ≤ 450m ; 9 . Ability willingness give write informed consent comply requirement study . 1 . Life expectancy le 12 month due noncardiac condition ; 2 . ACC/AHA Stage D Heart Failure ; 3 . Left ventricular ejection fraction ≤ 15 % ; 4 . Hypotension ( systolic pressure &lt; 90 mm Hg ) requirement inotropic support mechanical hemodynamic support ; 5 . United Network Organ Sharing ( UNOS ) status 1 heart transplantation prior orthotopic heart transplantation ; 6 . Untreated clinically significant coronary artery disease require revascularization ; 7 . CABG within prior 30 day ; 8 . Percutaneous coronary intervention within prior 30 day ; 9 . Severe Chronic Obstructive Pulmonary Disease ( COPD ) require continuous daytime home oxygen chronic oral corticosteroid therapy ; 10 . Previous surgical mitral valve bioprosthesis , mitral annuloplasty , transcatheter mitral valve procedure ; 11 . Positive pregnancy test , woman child bear potential use highly effective method contraception ; 12 . Mitral valve area &lt; 4.0 cm2 assess planimetry mitral valve ; 13 . Subjects transesophageal echocardiography contraindicate high risk ; 14 . Mitral leaflet anatomy may preclude MitraClip implantation : 1 . Perforated mitral leaflet cleft , lack primary secondary chordal support ; 2 . Severe calcification grasp area ; 3 . Rheumatic valve disease . 15 . Previously implanted Cardiac Resynchronization Therapy Defibrillator ( CRTD ) system ; 16 . Stroke transient ischemic event within 30 day randomization ; 17 . Modified Rankin Scale &gt; 4 disability ; 18 . Need emergent urgent surgery reason plan cardiac surgery within next 12 month ; 19 . Severe renal impairment define Estimated Glomerular Filtration Rate ( eGFR ) &lt; 30 mL/min/1.73m2 calculate Modification Diet Renal Disease ( MDRD ) formula ; 20 . Severe anemia require transfusional support therapy erythropoietin ; 21 . Physical evidence rightsided congestive heart failure echocardiographic evidence moderate severe right ventricular dysfunction ; 22 . Aortic valve disease require surgery transcatheter intervention ; 23 . Significant tricuspid valve disease require surgical intervention severe tricuspid regurgitation ; 24 . Active infection require antibiotic therapy ; 25 . Active endocarditis active rheumatic heart disease leaflet degenerate rheumatic disease ; 26 . Echocardiographic evidence intracardiac mass , thrombus vegetation ; 27 . Any condition make unlikely patient able complete protocol procedure ( include compliance guideline direct medical therapy ) followup visit ; 28 . Presence follow : 1 . Pulmonary artery systolic pressure ( PASP ) &gt; 70 mm Hg confirm right heart catheterization ; 2 . Infiltrative cardiomyopathy . 29 . Any condition ( ) would compromise safety patient judge site principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MitraClip</keyword>
	<keyword>Cardiovascular resynchronization therapy</keyword>
	<keyword>Six minute walk test</keyword>
	<keyword>Mitral regurgitation</keyword>
	<keyword>CRT-D</keyword>
</DOC>